Neonc Technologies Holdings Inc (NTHI)
NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) is a clinical-stage biopharmaceutical company focused on developing therapies for intracranial malignancies. The company’s pipeline includes NEO100, a purified form of perillyl acid that is being evaluated in a Phase IIa clinical trial, and NEO212, a conjugated compound combining temozolomide and perillyl alcohol that is being studied in Phase I/II trials for oral use in primary brain cancers. Target indications mentioned in the source include meningioma, high-grade gliomas, glioblastoma, and secondary brain cancers. Founded in 2005 and headquartered in Calabasas, California, the company was previously known as NAS-ONC, Inc. before adopting its current name in 2009.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-NTHI
|
$3.59
|
6.9% Upside
|
Fair
|
$16
|
376.9% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 25, 2026
|
-2.2x
|
-6.5x
|
—
|
84.802 M
|
86.306 M
|
0.4%
|
34.9%
|
-101.6
|
—
|
56.2%
|
